Financial Data and Key Metrics Changes - For Q3 2025, total revenue was reported at $14.3 million, a significant increase from a negative revenue of $1.8 million in Q3 2024 [21] - Net YCANTH revenue for Q3 2025 was $3.6 million, compared to negative $1.9 million in Q3 2024, reflecting improved demand and sales [21][22] - GAAP net loss for Q3 2025 was $0.2 million, or $0.03 per share, compared to a GAAP net loss of $22.9 million, or $4.88 per share in Q3 2024 [24] Business Line Data and Key Metrics Changes - Dispensed applicator units of YCANTH reached 14,093 in Q3 2025, representing a 5% sequential growth from the previous quarter [11] - Year-to-date dispensed applicator units increased to 37,642 for the nine months ended September 30, 2025, a 120% increase compared to the same period in 2024 [7] Market Data and Key Metrics Changes - The company received $18 million in cash milestone payments from Torii in 2025, with $10 million received in Q3 upon approval of YCANTH for molluscum in Japan [8] - Positive feedback from the European Medicines Agency indicated no further phase III studies are needed for YCANTH's approval for molluscum in the EU, with a filing anticipated in Q4 2026 [9][10] Company Strategy and Development Direction - The company aims to establish YCANTH as a leading therapy for multiple skin lesions, expanding its use beyond dermatology into pediatric and primary care [7][10] - The development of VP-315 for basal cell carcinoma is positioned as a potential standard of care, with plans for a phase III study design confirmed by the FDA [11][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of YCANTH, citing a strong foundation for future growth and the potential for multiple approvals across major pharmaceutical markets [4][9] - The company is focused on maintaining a highly efficient operating model while exploring strategic partnerships to advance its pipeline [26][19] Other Important Information - The company plans to launch YCANTH Rx, a non-dispensing pharmacy, in Q4 2025 to streamline the prescription process for healthcare providers [15] - The sales force has expanded to 45 representatives, with plans to increase to 50 in 2026 [15] Q&A Session Summary Question: Can you further speak to the YCANTH demand that you're seeing in Q4? - Management noted that momentum from September has continued into Q4, with expectations of increased demand [31] Question: What kind of counter-detailing are you seeing, and what has been the prescriber feedback on Zilretc? - Management views the Zilretc launch positively, as it raises awareness about the need to treat molluscum, while YCANTH remains a best-in-class option [32] Question: When do you expect sales force productivity to fully ramp? - Management indicated that new sales representatives typically take a few months to ramp up, with expectations for productivity to increase in early 2026 [36] Question: Why is there a 12-month timeline for the EU filing despite no additional clinical trials required? - Management explained that sequential steps, including securing a pediatric waiver, are necessary for the EU filing, which adds time to the process [38] Question: What feedback have you received regarding YCANTH RX? - Feedback has been positive, with the new pharmacy model expected to simplify the prescription process for clinicians and patients [45] Question: How should we think about seasonality impact in Q4 sales? - Management expects traditional slowdowns in November and December but anticipates increased doctor visits in the cold and flu season could boost diagnoses of molluscum [50]

Financial Data and Key Metrics Changes - The combined net revenue for Q3 2025 was approximately $3.1 million, representing a 4% increase compared to Q2 2025 revenue of approximately $3 million [4][18] - Loss from operations decreased by $24,000 from $7.2 million in Q3 2024 to $7.3 million in Q3 2025 [19] - Non-GAAP recurring EBITDA for Q3 2025 was a net loss of $8.9 million, compared to a loss of $9.2 million in Q3 2024 [20] - Net loss attributable to common shareholders decreased by $352,000 from $9.9 million in Q3 2024 to $9.5 million in Q3 2025 [20] Business Line Data and Key Metrics Changes - Mytesi prescription volume increased by approximately 0.9% in Q3 2025 over Q2 2025, but decreased by 3.6% compared to Q3 2024 [18] Company Strategy and Development Direction - The company aims to negotiate business development partnerships for licensed rights to develop and commercialize late-stage health products, focusing on generating non-dilutive funding [5][21] - Key late-stage initiatives include orphan indications of Crofelemer for intestinal failure associated with MVID and cancer therapy-related diarrhea [5][10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about multiple expected near-term catalysts for Crofelemer, viewing them as significant and potentially transformative for patients and stakeholders [21] - The company anticipates that these catalysts will lead to collaborations, business development, and licensing deals, supporting late-stage products and programs towards regulatory approval [21] Other Important Information - Crofelemer has shown a groundbreaking reduction of parenteral support of up to 37% for intestinal failure patients, which is significant given the lack of approved treatments for MVID [8][9] - The company is in discussions with multiple potential animal health partners to expand the use of Canalivia for general diarrhea in dogs [14] Q&A Session Summary - No specific questions and answers were provided in the content, thus this section is not applicable.

Financial Data and Key Metrics Changes - Revenue for Q3 2025 reached $22.9 million, a 232% increase year-over-year from $6.9 million in Q3 2024 and up from $19.7 million in Q2 2025 [11] - Gross profit margins expanded from 8% in Q2 to 11% in Q3, indicating improved operational efficiencies alongside revenue growth [11] - Operating loss for the quarter was $9 million, which included a $5.6 million non-cash stock-based compensation charge, while the adjusted operating loss was $3.4 million, down from $5.2 million in Q2 [12] Business Line Data and Key Metrics Changes - The company added an 11th new market, Fort Myers, Florida, contributing to increased gallons delivered and unlocking volume-based supplier discounts, which helped increase profit margins from 8% to 11% [5] - The energy division's pipeline includes projects for municipalities and commercial facilities, focusing on on-site power generation, advanced battery storage, and smart microgrid control systems [17][19] Market Data and Key Metrics Changes - The company is focusing on high-demand sectors such as healthcare and large-scale commercial facilities that require continuous power, indicating a strategic shift towards reliability and resilience [6] - The demand for smart microgrids and distributed infrastructure is intensifying as energy needs grow, particularly in relation to AI and data centers [23][24] Company Strategy and Development Direction - The company aims to create a fully connected energy ecosystem that integrates current fueling needs with future clean infrastructure [10] - The strategy includes deepening presence in key markets with mobile fuel delivery and advancing opportunities in renewable distributed infrastructure [10] - The company is positioned to address the urgent need for power generation, storage, and distribution, as highlighted by industry leaders [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's trajectory towards profitability, emphasizing that revenue growth, margin expansion, and disciplined cost management are key to achieving sustainable positive cash flow [25] - The company is optimistic about future energy demands and its ability to provide critical energy solutions, as indicated by discussions with industry leaders [8][9] Other Important Information - The company has taken steps to strengthen liquidity by refinancing its truck fleet and streamlining its debt profile, which enhances financial flexibility [13] - Management highlighted the importance of partnerships in solar hardware and battery storage to enhance offerings and competitive positioning [7] Q&A Session Summary Question: Details on energy division projects - The energy division's pipeline includes projects for municipalities and commercial facilities, focusing on on-site power generation, advanced battery storage, and smart microgrid systems [17][19] Question: Sustainability of margin improvements - Margin expansion is sustainable due to structural changes in the business, including optimized routes and increased gallons delivered, which lower per-unit costs [21][22] Question: Impact of urgent energy needs on NextNRG - The growing demand for energy, especially tied to AI and data centers, positions NextNRG favorably as it offers integrated solutions for power generation, storage, and distribution [23][24] Question: Timeline for sustainable positive cash flow - The path to positive cash flow is linked to continued revenue growth, further margin expansion, and disciplined spending, with a clear trend towards narrowing losses [25]

Financial Data and Key Metrics Changes - Revenue for Q3 2025 totaled $0.3 million, up from $0.1 million in Q3 2024, indicating a significant increase [9] - Gross profit improved to -$0.2 million in Q3 2025 from -$0.3 million in the same period last year, reflecting a better revenue mix [9] - Operating loss decreased to $11.5 million in Q3 2025 from $12.4 million in Q3 2024 [10] - Net loss narrowed to $11 million in Q3 2025 compared to $12.6 million in Q3 2024 [10] - As of September 30, 2025, the company held $52.6 million in cash and cash equivalents [11] Business Line Data and Key Metrics Changes - The company is focused on securing design wins with OEMs for its radar technology, with significant progress reported in collaborations with major OEMs [3][4] - A top Japanese OEM has ordered radar kits for Level 4 development, indicating strong demand for Arbe's technology [4] - Non-automotive projects are seeing increased demand, particularly in the defense sector and maritime applications [6][7] Market Data and Key Metrics Changes - Global economic shifts are causing some OEMs to delay new model launches, impacting decision timelines for autonomous driving solutions [5] - Despite these delays, Arbe's market position is strengthening, with expectations to secure key European OEM programs in the near term [5][11] Company Strategy and Development Direction - The company aims to be the key enabler for automated driving programs, with a focus on high-resolution radar technology [8] - Arbe expects initial revenues from its chipsets to begin in 2027, ramping up in 2028 as production scales [6] - The strategy includes expanding into non-automotive sectors, with a strong emphasis on defense and maritime applications [6][7] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about securing four design wins with OEMs in the next three quarters, with decisions expected from at least five OEMs [14] - The company anticipates a significant ramp-up in revenues from non-automotive sectors in 2026, alongside expected revenues from China [26] - Adjusted EBITDA expectations for 2025 remain unchanged at a loss of $29 million to $35 million, reflecting ongoing investments in growth [11] Other Important Information - The company won two prestigious automotive technology industry awards, highlighting its technological advancements in radar systems [7] - A new board member with extensive automotive industry experience was welcomed, enhancing the company's strategic capabilities [8] Q&A Session Summary Question: Is the guidance for four design wins referring to four separate OEMs? - Yes, it refers to four different OEMs, with decisions expected from at least five OEMs in the next three quarters [14] Question: What factors could swing the revenue guidance for Q4 from low to high? - The timing of customer decisions on NRE programs will significantly impact revenue recognition in Q4 [17] Question: Can you provide insights into the conversations with OEMs and reasons for decision delays? - Dialogues with OEMs are positive, but earlier delays were due to uncertainty around tariffs; now, a clearer path to decisions is emerging [23] Question: How should revenue and OpEx be modeled for 2026 and 2027? - Most revenues in 2026 are expected from non-automotive sectors, with stable OpEx levels anticipated as the automotive ramp-up occurs [26][27]

Financial Data and Key Metrics Changes - For fiscal 2025, the company reported revenue of $18.5 billion, a 6% increase compared to the prior year, with organic revenue growth of 7% [16][20] - Adjusted operating income for the fourth quarter was $289 million, growing 6% on a constant currency basis, while full-year adjusted operating income was $981 million, up 12% [17][18] - The adjusted EPS for the fourth quarter was $0.57, a 6% increase, and for the full year, it was $1.82, reflecting almost 20% growth [20][21] - The consolidated leverage ratio improved to 3.25 times, the lowest level in nearly 20 years, down from 3.4 times a year ago [21][22] Business Line Data and Key Metrics Changes - The FSS US segment grew organic revenue by 14% in the fourth quarter, driven by workplace experience and collegiate hospitality [8][16] - The international segment also reported consistent double-digit organic revenue growth of 14% in the fourth quarter, with strong contributions from the U.K., Canada, and Latin America [12][13] - The healthcare segment achieved its best performance in over two years, with significant new business wins contributing to growth [9][10] Market Data and Key Metrics Changes - The company experienced an industry-leading client retention rate of 96.3%, contributing to a net new business growth of 5.6% [6][7] - The collegiate sports business saw double-digit revenue growth, with per capita rates up 14% year over year [9][10] - The global supply chain added over $1 billion in new purchasing spend for the second consecutive year, primarily from various sectors including healthcare and education [13][14] Company Strategy and Development Direction - The company is focused on delivering exceptional hospitality services and maintaining high client retention rates, with a goal of achieving net new business growth of 4-5% in fiscal 2026 [7][23] - Strategic investments are being made in advanced technologies to enhance operational efficiencies and client service capabilities [19][22] - The company aims to leverage its strong new business pipeline and expand its presence in various sectors, including healthcare and collegiate sports [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, citing strong new business wins and high retention rates as key drivers for future performance [4][25] - The company anticipates organic revenue growth of $19.45 billion to $19.85 billion for fiscal 2026, representing a growth of 7%-9% [22][23] - Management acknowledged the impact of inflation, estimating it around 3% as they continue to manage the macro environment effectively [14][21] Other Important Information - The company has taken decisive actions to reduce future medical expenses related to elective lifestyle prescriptions, which are expected to positively impact costs going forward [18][19] - The company is committed to optimizing capital allocation priorities, including increasing dividends and stock repurchases [22][23] Q&A Session Summary Question: Can you delve into the shift in timing for new account openings? - Management indicated that the shift occurred across multiple businesses, including corrections and healthcare, and was client-driven rather than company-driven [30][31] Question: What is the expected cadence for the UPenn contract in 2026? - The UPenn contract will begin operations in February and will be staged over several months, with expectations for significant new business contributions throughout the year [32][33] Question: Can you discuss the margin trajectory with new wins? - Management noted that while there may be some incremental startup costs associated with new contracts, these will be offset by productivity improvements and efficiency initiatives [37][41] Question: What is the outlook for retention rates moving forward? - Management expressed a strong commitment to maintaining a retention rate above 95%, with aspirations to achieve even higher levels [99][101] Question: Can you elaborate on the restructuring measures in the international business? - The restructuring is aimed at streamlining SG&A and optimizing operations, despite the international segment's strong growth performance [75][76]

Financial Data and Key Metrics Changes - For Q3 2025, the company reported a loss from operations of $4 million, compared to a loss of $3 million in Q3 2024, primarily due to increased R&D expenses of $800,000 and additional administrative expenses of $400,000 [30][31] - The company reported revenue for the first time in its history, approximately $240,000, reflecting only 22 days of revenue from a single clinic [31][32] - As of September 30, 2025, the company had approximately $7.1 million in cash and cash equivalents, with total cash potentially reaching $10.3 million [31] Business Line Data and Key Metrics Changes - The company has advanced its drug approval applications for Ketaphree, NRx 100, and NRx 101, and has expanded its NRx 101 pipeline [3][4] - The acquisition of Durra Medical has initiated revenue generation, with plans to grow from two clinics to six or more by year-end [12][32] - The company anticipates significant revenue growth from short-term multimodality treatments that are already reimbursed at higher levels [13] Market Data and Key Metrics Changes - The market for ketamine is projected at approximately $750 million, with the company aiming to provide a preservative-free formulation [23] - The estimated market for NRx 101, targeting suicidal bipolar depression, is in excess of $1 billion [28] Company Strategy and Development Direction - The company aims to transform the treatment of severe depression and PTSD through innovative therapies combining D-cycloserine and TMS [4][11] - The strategy includes expanding the network of interventional psychiatry clinics and enhancing shareholder value through drug development and clinic acquisitions [30][33] - The company is focused on addressing the national crisis of suicide and improving treatment options for mental health disorders [30] Management's Comments on Operating Environment and Future Outlook - Management views the recent quarter as a watershed moment in the treatment of severe depression and PTSD, with promising data supporting their therapies [4][11] - The company is optimistic about the FDA's receptiveness to accelerated approval applications for NRx 100 and NRx 101, especially given the significant unmet medical need [25][40] - The leadership team is actively engaging with military and veterans' affairs leaders to address suicide prevention [20][30] Other Important Information - The company holds rights to over 70 patents related to the use of D-cycloserine in treating depression and PTSD [7] - The FDA has granted breakthrough therapy designation for NRx 101, and the company is pursuing both NDA and ANDA pathways for its products [18][24] Q&A Session Summary Question: Can you clarify the unique benefits of DCS compared to ketamine in treatment? - Management explained that DCS acts as a mixed agonist-antagonist and enhances neuroplasticity, which may improve TMS effectiveness [34][35] Question: What is the procedure for using DCS in conjunction with TMS? - The company has an expanded access protocol for DCS, allowing physicians to access it for treatment while collecting data on outcomes [38] Question: What feedback has been received regarding the accelerated approval strategy for NRx 100? - Management indicated that they expect to hear about the CMPV this year and are preparing to submit real-world data to support their NDA filing [39][40] Question: How will the company ensure adequate supply if the FDA bans preservative-containing formulations? - The company has a manufacturing capacity that could meet the entire U.S. demand for ketamine, utilizing a blow-fill seal presentation for production [41] Question: What is the commercialization strategy for NRx 100 and NRx 101? - NRx 100 will likely require a medical science liaison approach, while NRx 101 may necessitate a sales force due to its specific target market [44][45]

Financial Data and Key Metrics Changes - For Q3 2025, the company reported a loss from operations of $4 million, compared to a loss of $3 million in Q3 2024, primarily due to increased R&D expenses of $800,000 and additional administrative expenses of $400,000 [30][31] - The company reported revenue for the first time in its history, approximately $240,000, reflecting only 22 days of revenue from a single clinic [31][32] - As of September 30, 2025, the company had approximately $7.1 million in cash and cash equivalents, which would have been $10.3 million if not for a subscription receivable [31][32] Business Line Data and Key Metrics Changes - The company has advanced its drug approval applications for Ketaphree, NRx 100, and NRx 101, and has expanded its NRx 101 pipeline [3][4] - The acquisition of Durra Medical has initiated revenue generation, with plans to grow from two clinics to six or more by year-end [12][32] - The company anticipates significant revenue growth from short-term multimodality treatments that are already reimbursed at higher levels [13] Market Data and Key Metrics Changes - The market for ketamine is projected at approximately $750 million, with the company aiming to provide a preservative-free option [23] - The estimated market for NRx 101, targeting suicidal bipolar depression, is in excess of $1 billion [28] Company Strategy and Development Direction - The company aims to transform the treatment of severe depression and PTSD through innovative therapies combining D-cycloserine and TMS [4][11] - The strategy includes expanding the network of interventional psychiatry clinics and engaging with the payer community to adapt to changing treatment paradigms [12][15] - The company is focused on advancing drug development initiatives and planned clinic acquisitions to build long-term shareholder value [33] Management's Comments on Operating Environment and Future Outlook - Management views the recent quarter as a watershed moment in the treatment of severe depression and PTSD, with promising data supporting their therapies [4][11] - The leadership team is optimistic about the potential for accelerated drug approvals and the impact on addressing the national crisis of suicide [30][46] - The company believes it is better positioned than ever to build shareholder value and address mental health challenges [30] Other Important Information - The company holds rights to over 70 patents related to the use of D-cycloserine in treating depression and PTSD [7] - The FDA has granted breakthrough therapy designation for NRx 101, and the company is pursuing two approval pathways for its ketamine product [18][24] Q&A Session Summary Question: Can you clarify the DCS results with TMS and its unique position? - The company explained that DCS is a mixed agonist-antagonist and has shown to enhance neuroplasticity, which is critical for its effectiveness in combination with TMS [34][35] Question: What feedback have you received on the accelerated approval strategy for NRx 100? - The company indicated that they expect to hear about the CMPV this year and are preparing to file for accelerated approval with substantial real-world data [39][40] Question: How will you position Hope to become an early adopter of the 1D protocol? - The company has partnered with AMPA and is the first site in Florida to implement the 1D protocol, which is readily deployable [42][43] Question: What is your commercialization strategy for NRx 100 and 101? - The company plans to utilize medical science liaison functions for NRx 100 and anticipates building a sales force for NRx 101, with potential partnerships with larger commercial entities [44][45]

Codere Online Luxembourg (NasdaqCM:CDRO) Q3 2025 Earnings Call November 17, 2025 08:30 AM ET Company ParticipantsMoshe Edree - Executive Vice ChairmanJeff Stantial - Managing Director of Equity ResearchAviv Sher - CEOOscar Iglesias - CFOGuillermo Lancha - Head of Investor RelationsConference Call ParticipantsRyan Sigdahl - Senior Research AnalystOperatorLadies and gentlemen, thank you for joining us and welcome to the Codere Online Third Quarter 2025 financial results. After today's prepared remarks, we wil ...

Financial Data and Key Metrics Changes - Revenue for Q3 2025 reached $22.9 million, representing a 232% year-over-year increase from $6.9 million in Q3 2024 and up from $19.7 million in Q2 2025 [12] - Gross profit margins expanded from 8% in Q2 to 11% in Q3, indicating improved operational efficiencies alongside revenue growth [12][13] - Operating loss for the quarter was $9 million, which included a $5.6 million non-cash stock-based compensation charge, while the adjusted operating loss was $3.4 million, down from $5.2 million in Q2 [12][13] Business Line Data and Key Metrics Changes - The company added an 11th new market, Fort Myers, Florida, contributing to increased gallons delivered and unlocking volume-based supplier discounts, which helped increase profit margins from 8% to 11% [5] - The energy division's pipeline includes projects for municipalities and commercial facilities, focusing on on-site power generation, advanced battery storage, and smart microgrid control systems [19][20] Market Data and Key Metrics Changes - The company is focusing on high-demand sectors such as healthcare and large-scale commercial facilities that require continuous power, reflecting a strategic shift towards reliability and resilience [6] - The demand for smart microgrids and distributed infrastructure is intensifying as energy needs grow, particularly in relation to AI and data centers [24] Company Strategy and Development Direction - The company aims to create a fully connected energy ecosystem that integrates generation, storage, distribution, and fueling, positioning itself as a leader in the energy transition [4][10] - Future strategies include deepening market presence with mobile fuel delivery and advancing renewable distributed infrastructure [11] Management's Comments on Operating Environment and Future Outlook - Management highlighted the urgent need for expanded energy generation and infrastructure, emphasizing that the current grid cannot keep pace with accelerating demand [9][24] - The company is optimistic about its position to address energy challenges, with a focus on scaling operations and improving margins [10][26] Other Important Information - The company has taken steps to strengthen liquidity by refinancing its truck fleet and streamlining its debt profile, enhancing financial flexibility [15] - The CEO is now free from non-compete restrictions, allowing the company to fully engage in all forms of EV charging [17] Q&A Session Summary Question: Details on energy division projects - The energy division's pipeline includes projects for municipalities and commercial facilities, focusing on on-site power generation, advanced battery storage, and smart microgrid systems [19][20] Question: Sustainability of margin improvements - Margin expansion is sustainable due to structural changes in the business, including optimized routes and increased gallons delivered, which lower per-unit costs [22][23] Question: Impact of urgent energy demand on NextNRG - The growing demand for energy, especially related to AI and data centers, positions NextNRG favorably for providing integrated energy solutions [24] Question: Timeline for sustainable positive cash flow - The path to positive cash flow is linked to continued revenue growth, further margin expansion, and disciplined spending, with improvements expected as new markets mature [25][26]

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $7.7 million, representing a 24% year-over-year increase [13] - Platform revenue was $2.6 million, up 15% year-over-year, while solutions revenue reached $5.1 million, up 30% year-over-year [13] - Gross margin improved from 65% a year ago to 69.1% in Q3 2025, with non-IFRS gross margin rising from 72.7% to 74.8% [16] - Adjusted EBITDA improved to negative $2.6 million in Q3 2025 compared to negative $2.8 million in Q3 2024 [17] - Cash and short-term bank deposits at the end of the quarter were $30.6 million, supporting continued investments [18] Business Line Data and Key Metrics Changes - The company processed 429,000 transactions in Q3, a 27% increase year-on-year, marking the 23rd consecutive quarter of record transactions [4] - Unique buyer users were approximately 20,600, and the number of carriers with more than five bookings increased to 77 [4] - Solutions revenue growth was anticipated to be stronger than the 30% year-on-year growth delivered, impacted by longer sales cycles due to tariffs and macroeconomic conditions [9] Market Data and Key Metrics Changes - Air cargo volumes increased by 4% compared to Q3 2024, despite challenges in trans-Pacific e-commerce volumes [5] - Average global air cargo rates decreased by 6% compared to Q3 last year, reflecting market volatility [5] - The overall global trade is up on the year, but trade with the U.S. has seen a slight decline [30] Company Strategy and Development Direction - The company is focused on expanding airline coverage in Asia and enhancing multimodal capabilities [4][6] - A strategic partnership with Visa and TransCard was announced to provide modern financing solutions for freight forwarders and importers/exporters [6][7] - The launch of the new multimodal rate management and quoting SaaS product, WebCargo Rate & Quote Ocean, aims to unify air and ocean quoting [8] Management's Comments on Operating Environment and Future Outlook - Management noted that while there is less uncertainty than earlier in the year, tariffs and macroeconomic conditions still create friction for imports to the U.S. [28] - The company anticipates meaningful revenue contributions from ocean bookings in the midterm, with significant growth expected by 2028 [44][45] - The focus remains on achieving adjusted EBITDA break-even by Q4 2026, with continued revenue growth and disciplined cost management [18][20] Other Important Information - The company closed the quarter with a cash burn of about $10 million for 2025, down from $15 million in 2024 [20] - The company expects to end the year with cash and equivalents of approximately $27 million [20] Q&A Session Summary Question: Can you discuss the contribution margin and growth opportunities? - Management acknowledged the balance between growth and achieving break-even EBITDA, emphasizing efficiency improvements and potential AI-driven efficiencies [25][26] Question: How is tariff volatility impacting shipping volumes? - Management indicated that while there is some stabilization, uncertainty and higher tariffs still create friction for imports, affecting the ability to secure large contracts [29][31] Question: What is the current penetration of the platform in various markets? - Management stated that penetration varies by geography, with high penetration in Europe, moderate in the U.S., and low in Asia [35] Question: How will the Visa partnership impact opportunities? - The partnership is expected to enhance payment solutions, potentially increasing average take rates with airlines [40] Question: When will ocean bookings start contributing significantly to revenue? - Significant revenue from ocean bookings is not expected until 2028, with minor contributions anticipated in 2027 [44][45] Question: What is the proportion of recurring versus non-recurring revenue in solutions? - Management indicated that a very large majority of solutions revenue is recurring, with non-recurring revenue not exceeding 5% [59][60]